AdaptHealth projects $490M-$520M 2026 EBITDA amid portfolio reset and west coast contract headwinds (NASDAQ:AHCO)
· seekingalpha.com
AdaptHealth (AHCO) Q2 2026 earnings call recap: 16% organic growth, Diabetes divestiture, guidance reset, capitation & supplier risks.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...